Arcus Biosciences kept reporting promising kidney cancer data and a long cash runway, yet long-term holders still saw their capital shrink. For Arcus Biosciences shareholders, the loss from the start of the year was 29.6%, including dividends. If you had been weighing an investment back on 2026-01-01, looking at bullish price targets on one side and concerns about regulatory risk and partner dependence on the other, which signals would have deserved the most attention? A Narrative on Simply...
Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock today, the key question is whether the current share price is reasonable when compared with the revenue Arcus is generating. Over the past 5 years the share price has fallen 44.6%, which puts the spotlight firmly on whether the business now justifies its market value through its sales profile. New kidney cancer data...
Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, but shares took a swim.
Detailed price information for Arcus Biosciences Inc (RCUS-N) from The Globe and Mail including charting and trades.
Arcus Biosciences recently announced it would host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. A particularly important aspect is the breadth of casdatifan data, including TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a...
HAYWARD, Calif., September 24, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $26.39, which was the closi
Arcus Biosciences (RCUS) has an average rating of buy and mean price target of $39.27, according to
Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.
HAYWARD, Calif., September 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company’s common stock at an exercise price per share of $29.06, which was t
This is the newest page. Registered accounts read further back.